---
title: "CARsgen Reports Promising Early Results for Allogeneic BCMA CAR-T Therapy in Relapsed Primary Plasma Cell Leukemia"
description: "CARsgen Therapeutics Holdings Ltd. has reported promising early results for its allogeneic BCMA-targeted CAR-T therapy, CT0596, in treating relapsed primary plasma cell leukemia (pPCL). Preliminary da"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261744860.md"
published_at: "2025-10-19T06:00:44.000Z"
---

# CARsgen Reports Promising Early Results for Allogeneic BCMA CAR-T Therapy in Relapsed Primary Plasma Cell Leukemia

> CARsgen Therapeutics Holdings Ltd. has reported promising early results for its allogeneic BCMA-targeted CAR-T therapy, CT0596, in treating relapsed primary plasma cell leukemia (pPCL). Preliminary data from two enrolled patients showed both achieved stringent complete response post-infusion, with robust CAR-T cell expansion and manageable safety profiles. Adverse events included cytokine release syndrome and hematologic toxicities, but no significant organ toxicities were noted. These findings support further investigation of CT0596 in plasma cell neoplasms.

CARsgen Therapeutics Holdings Ltd. has announced preliminary clinical data for its allogeneic BCMA-targeted CAR-T therapy, CT0596, developed using the THANK-u Plus™ platform. The therapy is currently being evaluated in investigator-initiated trials for the treatment of primary plasma cell leukemia (pPCL), a rare and aggressive plasma cell malignancy with limited treatment options. As of October 17, 2025, two patients with relapsed or refractory pPCL had been enrolled. Both patients achieved stringent complete response following CT0596 infusion, with robust CAR-T cell expansion and manageable safety profiles. Adverse events included cytokine release syndrome and hematologic toxicities, but no significant organ toxicities were observed. These results have already been presented and support continued investigation of CT0596 in plasma cell neoplasms. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01459) on October 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [02171.HK - CARSGEN-B](https://longbridge.com/en/quote/02171.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 科濟藥業-B 提交了同種異體 BCMA CAR-T 療法 CT0596 的雙重 IND 申請 | CARsgen Therapeutics Holdings Ltd. 已向國家藥品監督管理局（NMPA）提交了兩份針對其同種異體 BCMA 靶向 CAR-T 細胞療法 CT0596 的臨牀試驗申請（IND）。這些申請旨在啓動針對復發/難治性 | [Link](https://longbridge.com/en/news/270931052.md) |
| 科濟藥業-B 與 Dispatch Bio 公司啓動實體瘤治療的臨牀合作 | CARsgen Therapeutics Holdings Ltd. 宣佈與 Dispatch Bio 達成臨牀合作，評估 Dispatch 的 Flare 平台與 CARsgen 的 zevorcabtagene autoleucel（z | [Link](https://longbridge.com/en/news/272274220.md) |
| 05:30 ET 真實世界證據：後脛腱退化患者的疼痛和功能評分有所改善 | 來自大學足踝研究所和再生實驗室的醫生髮表了一項經過同行評審的研究，探討了臍帶結締組織同種異體移植物用於治療對保守治療無反應的後脛腱退化（PTTD）患者。研究顯示，接受同種異體移植物的患者在疼痛和生活質量方面有顯著改善，且未報告不良事件。這些 | [Link](https://longbridge.com/en/news/275740095.md) |
| 羅馬在通往鬥獸場的大道上砍伐老化的松樹 | 羅馬已經開始砍伐通往鬥獸場的林蔭大道上的老化松樹，因為測試顯示 36 棵樹中有 12 棵不穩定。這一決定是在三棵樹倒塌並造成三人受傷後做出的。這些松樹大約有 120 年的歷史，由於氣候變化和害蟲侵擾，變得脆弱。有關部門計劃用同種新樹替代被移 | [Link](https://longbridge.com/en/news/275907277.md) |
| 在新的 BCMA CAR T 療法 Anito Cel 臨牀前數據發佈後，評估 Arcellx (ACLX) 的估值 | Arcellx (ACLX) 的股票在其 BCMA CAR T 療法 anitocabtagene autoleucel 的新臨牀前數據發佈後受到關注。儘管最近的股價為 68.50 美元，但該公司在過去 90 天內經歷了 23.88% 的下 | [Link](https://longbridge.com/en/news/276053786.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.